| Methods |
Double‐blind, placebo‐controlled, parallel group
Block randomisation (4 per block) |
| Participants |
UK, single centre
37 patients: T: 18, C: 19
Age: 68 years
Male: 86%
Inclusion: neuroradiologically diagnosed ischaemic stroke with 24 hour BP > 135/85 mmHg
Enrolment within 96 hours of stroke onset |
| Interventions |
T: bendrofluazide 2.5 mg po daily
C: matching placebo
Rx: 7 days |
| Outcomes |
Casual and non‐invasive beat‐to‐beat arterial BP level, cerebral blood flow velocity, ECG and transcutaneous carbon dioxide levels within 70+/‐20 hours of cerebral infarction and 7 days later were measured
24‐hour BP monitoring with Spacelabs 90207 and brachial artery BP with validated semi‐automatic BP monitor (Omron 711) |
| Notes |
Exclusion: history of previous stroke, dysphagia, symptoms lasting < 24 hours, or presented > 76 hours after symptom onset (to allow for 24 hour BP monitoring to be performed prior to randomisation) |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Low risk |
Probably done |
| Allocation concealment? |
Low risk |
Probably done |
| Blinding? |
Low risk |
Probably done |
| Completeness of follow‐up |
Low risk |
38 participants randomised, 19 to each group |
